Table 2.
Risk factors and use of cardioprotective and immunosuppressive medications at 3 months after transplant (n = 825)a
| Variable Name | SA (n = 127) | White (n = 529) | Black (n = 62) | East Asian (n = 107) | P |
|---|---|---|---|---|---|
| BMI (kg/m2) | 26.6 ± 5d | 26.5 ± 5 | 26.4 ± 5 | 24.3 ± 4 | 0.0003 |
| Systolic BP (mmHg) | 127 ± 13d | 128 ± 15 | 128 ± 18 | 132 ± 13 | 0.040 |
| Diastolic BP (mmHg) | 77 ± 9 | 77.8 ± 9 | 77.7 ± 12 | 81 ± 9d | 0.040 |
| Total cholesterol (mmol/L) | 4.69 ± 1.2 | 4.71 ± 1.1 | 4.56 ± 1.2 | 4.61 ± 1.0 | 0.645 |
| HDL | 1.31 ± 0.5 | 1.30 ± 0.4 | 1.18 ± 0.4 | 1.25 ± 0.3 | 0.250 |
| LDL | 2.56 ± 0.8b | 2.63 ± 0.8 | 2.57 ± 0.9 | 2.61 ± 0.9 | 0.465 |
| Triglycerides | 1.89 ± 0.9 | 1.78 ± 0.9 | 1.77 ± 0.8 | 1.66 ± 0.6 | 0.112 |
| Renal function | |||||
| serum creatinine (μmol/L) | 137.5 ± 78c | 151.8 ± 116 | 174.8 ± 124 | 135.8 ± 73 | 0.058 |
| eGFR (ml/min per 1.73 m2) | 61.5 ± 28c | 55.6 ± 27 | 46.3 ± 23 | 53.9 ± 23 | 0.013 |
| acute rejection [N (%)] | 13 (9%) | 66 (12%) | 10 (15%) | 15 (13%) | 0.204 |
| delayed graft function [N (%)] | 15 (10%) | 47 (8%) | 13 (20%) | 14 (12%) | 0.074 |
| NODAT [N (%)] | 10 (7%) | 31 (5%) | 5 (7%) | 11 (10%) | 0.428 |
| Medications | |||||
| statin [N (%)] | 51 (40%) | 192 (36%) | 14 (22%) | 33 (31%) | 0.052 |
| ACEI [N (%)] | 26 (20%)b | 153 (29%) | 20 (32%) | 18 (17%) | 0.021 |
| ARB [N (%)] | 20 (16%) | 72 (13%) | 13 (20%) | 14 (13%) | 0.226 |
| NDCCB [N (%)] | 47 (37%) | 157 (29%) | 23 (37%) | 28 (26%) | 0.195 |
| DCCB [N (%)] | 34 (26%) | 120 (22%) | 13 (21%) | 26 (25%) | 0.618 |
| β blocker [N (%)] | 53 (41%) | 188 (35%) | 25 (40%) | 32 (29%) | 0.177 |
| α blocker [N (%)] | 4 (3%) | 32 (6%) | 4 (6%) | 2 (2%) | 0.152 |
| loop diuretic [N (%)] | 6 (4%)b | 56 (10%) | 9 (14%) | 4 (4%) | 0.01 |
| thiazide diuretic [N (%)] | 4 (3%) | 36 (7%) | 2 (3%) | 0 (0%) | 0.077 |
| other anti-hypertensives [N (%)] | 5 (3%) | 19 (3%) | 1 (1%) | 2 (2%) | 0.419 |
| insulin [N (%)] | 26 (20%)b | 51 (10%) | 8 (13%) | 14 (13%) | 0.002 |
| ASA [N (%)] | 18 (14%)d | 91 (17%) | 6 (10%) | 4 (4%) | 0.012 |
| allopurinol [N (%)] | 4 (3%) | 26 (5%) | 2 (3%) | 3 (3%) | 0.322 |
| colchicine [N (%)] | 0 (0%) | 7 (1%) | 0 (0%) | 0 (0%) | 0.199 |
| CsA [N (%)] | 54 (42%)b | 126 (23%) | 31 (50%) | 28 (26%) | 0.002 |
| tacrolimus [N (%)] | 71 (56%)a | 373 (71%) | 28 (45%) | 70 (65%) | <0.0001 |
| MMF [N (%)] | 93 (73%)c | 379 (72%) | 48 (77%) | 76 (71%) | 0.084 |
| MPA [N (%)] | 6 (4%) | 23 (4%) | 2 (3%) | 3 (3%) | 0.532 |
| azathioprine [N (%)] | 4 (3%)b | 8 (1%) | 1 (1%) | 1 (1%) | 0.264 |
| sirolimus [N (%)] | 5 (3%)b | 44 (8%) | 2 (3%) | 8 (7%) | 0.064 |
| prednisone [N (%)] | 104 (81%) | 389 (74%) | 45 (72%) | 86 (80%) | 0.26 |
ACEI, angiotensin converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; ASA, acetylsalicylic acid; CsA, cyclosporine A; DCCB, dihydropyridine calcium channel blocker; MMF, mycophenolate mofetil; MPA, mycophenolic acid; NDCCB, non-dihydropyridine calcium channel blocker.
a
Excludes patients censored before 3 months as the result of an event or loss to follow-up.
b
P < 0.01 for SA versus white.
c
P < 0.05 for SA versus black.
d
P < 0.01 for SA versus East Asian.